Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2:: Coordination of dendritic and CD8+ cell responses

被引:82
作者
Murphy, WJ
Welniak, L
Back, T
Hixon, J
Subleski, J
Seki, N
Wigginton, JM
Wilson, SE
Blazar, BR
Malyguine, AM
Sayers, TJ
Wiltrout, RH
机构
[1] Univ Nevada, Sch Med, Dept Microbiol, Reno, NV 89557 USA
[2] Sci Applicat Int Corp, Intramural Res Support Program, Frederick, MD 21702 USA
[3] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21702 USA
[4] Chiron Corp, Prot Therapeut, Emeryville, CA 94608 USA
[5] Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
关键词
D O I
10.4049/jimmunol.170.5.2727
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In cancer, the coordinate engagement of professional APC and Ag-specific cell-mediated effector cells may be vital for the induction of effective antitumor responses. We speculated that the enhanced differentiation and function of dendritic cells through CD40 engagement combined with IL-2 administration to stimulate T cell expansion would act coordinately to enhance the adaptive immune response against cancer. In mice bearing orthotopic metastatic renal cell carcinoma, only the combination of an agonist Ab to CD40 and IL-2, but neither agent administered alone, induced complete regression of metastatic tumor and specific immunity to subsequent rechallenge in the majority of treated mice. The combination of anti-CD40 and IL-2 resulted in significant increases in dendritic cell and CD8(+) T cell number in advanced tumor-bearing mice compared with either agent administered singly. The antitumor effects of anti-CD40 and IL-2 were found to be dependent on CD8(+) T cells, IFN-gamma, IL-12 p40, and Fas ligand. CD40 stimulation and IL-2 may therefore be of use to promote antitumor responses in advanced metastatic cancer.
引用
收藏
页码:2727 / 2733
页数:7
相关论文
共 32 条
[1]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[2]  
Buhlmann JE, 1999, J IMMUNOL, V162, P4373
[3]  
Clark LB, 1996, ADV IMMUNOL, V63, P43
[4]   Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas [J].
Funakoshi, S ;
Longo, DL ;
Murphy, WJ .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02) :93-101
[5]   RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].
FYFE, G ;
FISHER, RI ;
ROSENBERG, SA ;
SZNOL, M ;
PARKINSON, DR ;
LOUIE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696
[6]   Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy [J].
Fyfe, GA ;
Fisher, RI ;
Rosenberg, SA ;
Sznol, M ;
Parkinson, DR ;
Louie, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2410-2411
[7]   IL-2 mediates adjuvant effect of dendritic cells [J].
Granucci, F ;
Andrews, DM ;
Degli-Esposti, MA ;
Ricciardi-Castagnoli, P .
TRENDS IN IMMUNOLOGY, 2002, 23 (04) :169-171
[8]   Inducible IL-2 production by dendritic cells revealed by global gene expression analysis [J].
Granucci, F ;
Vizzardelli, C ;
Pavelka, N ;
Feau, S ;
Persico, M ;
Virzi, E ;
Rescigno, M ;
Moro, G ;
Ricciardi-Castagnoli, P .
NATURE IMMUNOLOGY, 2001, 2 (09) :882-888
[9]   The role of CD40 ligand in costimulation and T-cell activation [J].
Grewal, IS ;
Flavell, RA .
IMMUNOLOGICAL REVIEWS, 1996, 153 :85-106
[10]  
Gruys ME, 2001, CANCER RES, V61, P6255